A change to how the National Institutes of Health (NIH) accounts for multi-year grants, not a cut to NIH’s overall appropriation, is the mechanism behind one of the sharpest single-year drops in NIH award and success rates in decades. Under a policy directive from the Office of Management and Budget (OMB), NIH must now obligate the FULL multi-year cost of a competing award in the fiscal year it is made, rather than funding it year-by-year as it has for decades. The arithmetic is unforgiving for a flat or roughly flat topline budget: the same dollars fund fewer new grants.
What changed: annual increments to full up-front obligation
For most of NIH’s history, a multi-year award — a five-year R01, for example — was funded one year at a time. NIH obligated that year’s increment, then issued a non-competing continuation each subsequent year, contingent on progress and appropriations. Under the current lump-sum mandate, NIH must instead obligate the entire multi-year total in the award’s first year. A five-year R01 budgeted at $500,000 in direct costs per year, which previously required NIH to commit roughly $500,000 in year one, now requires the agency to commit the full $2.5 million up front, per the mechanism described in multiple outlets’ reporting on the policy, including Science/AAAS coverage of the policy’s effects.
The change doesn’t reduce NIH’s topline budget on paper. It reduces how many NEW competing awards that budget can fund in a given year, because dollars that would previously have covered years two through five of dozens of other awards are now front-loaded into year one of a smaller number of awards. Renewal and continuation funding for grants already in their later years is likewise squeezed by the same accounting shift.
The award numbers, as reported
Multiple trackers converge on a substantial year-over-year drop in new R01-equivalent awards, though the precise figures vary by source and methodology, and NIH’s own official success-rate tables for FY2025 are not yet fully finalized in the way prior fiscal years’ data is. Reported figures include:
- The number of investigators receiving new R01-equivalent awards fell from approximately 7,720 in FY2024 to approximately 5,885 in FY2025 — a decline of roughly 24% year-over-year, per NIH RePORTER-derived analysis.
- NIH’s own internal projections reportedly point to approximately 4,312 new competing research grants in FY2026, down from about 6,095 in FY2025 — a further decline of roughly 29%, if that projection holds.
- Science/AAAS reporting states NIH funded roughly 2,800 fewer new grants in FY2025 than the FY2021–24 average, and cites an NIH projection attributing roughly 970 fewer competing grants in FY2026 specifically to the lump-sum obligation requirement.
On success rates specifically, coverage is directionally consistent — sharply down — but the specific percentage cited depends on scope (all NIH research grants vs. R01-equivalents specifically) and on which tracker is doing the counting:
- United for Medical Research reported that only about 17% of NIH research-grant applicants received an award in FY2025, described as the lowest overall success rate in roughly 30 years.
- Separate, R01-equivalent-specific figures reported elsewhere show a decline from 21.6% (FY2023) to 18.7% (FY2024) to roughly 13.0% (FY2025).
- The funding rate for early-stage investigators (those within roughly 10 years of their terminal research degree) reportedly fell from about 26% in FY2024 to about 19% in FY2025.
Because these figures come from a mix of NIH-derived data, secondary trackers, and advocacy-organization analysis rather than a single finalized NIH source table, research offices citing specific percentages in institutional communications should treat them as directionally reliable but attribute the specific number to its source, and check NIH’s own RePORT success-rate tables directly once FY2025 figures are finalized there.
Why the effect isn’t evenly distributed
The lump-sum obligation requirement doesn’t cut every Institute or Center by the same amount, because Institutes vary in how many multi-year vs. single-year mechanisms they fund and in how much of their budget is already committed to non-competing continuations of prior awards. Reporting on the National Cancer Institute (NCI) specifically describes applicant odds falling from roughly 1-in-10 to roughly 1-in-25 — a steeper decline than the NIH-wide averages above, illustrating how much variation exists Institute to Institute even under one agency-wide mandate. Early-stage investigators, who typically have thinner track records and compete for the same shrinking pool of new (not competing-renewal) awards as established labs, appear to be absorbing a disproportionate share of the decline, per the ESI funding-rate figures above.
What this means for research administrators and PIs
For grants offices and principal investigators, the practical implications of a funding-rate compression driven by an accounting mechanism, rather than by an underlying budget cut, are distinct from a normal appropriations-driven tight year:
- Mechanism choice matters more. A funding line that requires NIH to obligate five years up front is structurally harder for NIH to fund than one built around shorter project periods or staged, milestone-based funding — worth factoring into award-mechanism selection where a legitimate scientific case exists for either.
- Payline volatility increases. Because fewer new awards are being made across the board, published paylines and percentile cutoffs by Institute are moving faster and are less predictable year to year than in a stable-budget environment — see CASRAI’s guide to NIH R01 success rates and paylines by Institute for how to read current, Institute-specific data rather than relying on prior-year benchmarks.
- Resubmission and revision planning becomes more consequential. With fewer slots available per cycle, the quality bar effectively rises even where review scores are unchanged in absolute terms; institutions may want to revisit internal proposal-development support and triage processes for A1 resubmissions.
- Continuation funding for multi-year awards already in progress is not automatically insulated. Because dollars are now committed up front for new awards, offices managing multi-year projects should confirm with program officers, rather than assume, that out-year funding for existing non-competing continuations is unaffected at their specific Institute.
This is a live, fast-moving budget and policy story tied to FY2026 appropriations; the specific award counts and success-rate percentages above should be treated as the most recent reported figures at time of writing, not final, audited NIH statistics, and are likely to be revised as NIH’s own FY2025 and FY2026 RePORT tables are finalized.
Frequently asked questions
Is NIH’s overall budget being cut?
The lump-sum funding mandate is an accounting/obligation-timing change, not, by itself, a claim about NIH’s topline appropriation. Its effect is on how many new competing awards a given annual budget can support, because multi-year commitments are now funded in full up front rather than spread across the years of the project period. Separate appropriations and indirect-cost policy debates are also affecting NIH funding in the same period — see CASRAI’s coverage of the NIH 15% indirect cost cap for a related but distinct policy thread.
Does this affect all NIH award mechanisms equally?
No. The effect is concentrated on mechanisms with longer project periods and larger total multi-year budgets, since those require the largest single-year obligation under the new rule. Institutes and Centers with a higher proportion of multi-year competing awards, and a larger share of their budget already tied up in non-competing continuations, appear to be affected more severely, as illustrated by NCI’s reported decline.
Where can I find my Institute’s current success rate and payline?
NIH’s own RePORT site publishes success-rate data by Institute and activity code once finalized; individual Institutes also post current fiscal-year paylines directly. CASRAI’s guide to finding and reading NIH R01 success rates and paylines by Institute walks through where to look and how to interpret the numbers.
